CII .	4	C	4
Sheet	1	of	1

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-153US1	Application No. 10/551,504	
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Hiroyuki Tsunoda et al.		
		Filing Date September 29, 2005	Group Art Unit 1647	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1	2004/0058393	03/01/2004	Fukishima et al.			
	A2	2002/0028178	3/1/2002	Hanna et al.			

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	
Initial	ID	Document
	A3	Reff et al., "A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications", Critical Reviews in Oncology and Hematology, 40:25-35, 2001.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.S./

Examiner Signature /Lorraine Spector/	Date Considered 03/23/2009
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant	t in conformance and not considered. Include copy of this form with